Who
Kamal Adawi
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, Fate Therapeutics; CFO and Corporate Secretary, Exagen.
In numbers
- Trades disclosed
- 19
- Buys
- 0
- Sells
- 4
- Bought
- $0
- Sold
- $62K
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 18 Sep 2019
- Last trade
- 15 Jan 2026
- Last filed
- 16 Jan 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 15 Jan 2026filed 16 Jan 2026 | FATE Fate TherapeuticsBiotechnology | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 15 Jan 2026filed 16 Jan 2026 | FATE Fate Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —75,000 at $0.00 | filing |
| 15 Jan 2026filed 16 Jan 2026 | FATE Fate Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —75,000 at $0.00 | filing |
| 15 Jan 2026filed 16 Jan 2026 | FATE Fate TherapeuticsBiotechnology | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 20 Oct 2025filed 21 Oct 2025 | FATE Fate Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —375,000 at $0.00 | filing |
| 20 Oct 2025filed 21 Oct 2025 | FATE Fate TherapeuticsBiotechnology | SEC FORM 4 Code A | —75,000 at $0.00 | filing |
| 4 Mar 2024filed 6 Mar 2024 | XGN ExagenDiagnostics & Labs | SEC FORM 4 Sold | $18K9,297 at $1.91 | filing |
| 4 Mar 2024filed 6 Mar 2024 | XGN ExagenDiagnostics & Labs | SEC FORM 4 Sold | $6,6603,487 at $1.91 | filing |
| 20 Feb 2024filed 22 Feb 2024 | XGN ExagenDiagnostics & Labs | SEC FORM 4 Code A | —75,000 at $0.00 | filing |
| 6 Feb 2024filed 8 Feb 2024 | XGN ExagenDiagnostics & Labs | SEC FORM 4 Sold | $13K6,738 at $1.95 | filing |
| 2 Mar 2023filed 3 Mar 2023 | XGN ExagenDiagnostics & Labs | SEC FORM 4 Sold | $8,4343,667 at $2.30 | filing |
| 27 Feb 2023filed 1 Mar 2023 | XGN ExagenDiagnostics & Labs | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 8 Feb 2023filed 10 Feb 2023 | XGN ExagenDiagnostics & Labs | SEC FORM 4 Sold | $16K5,821 at $2.69 | filing |
| 1 Mar 2022filed 2 Mar 2022 | XGN ExagenDiagnostics & Labs | SEC FORM 4 Code F | $23K3,241 at $7.12 | filing |
| 4 Feb 2022filed 8 Feb 2022 | XGN ExagenDiagnostics & Labs | SEC FORM 4 Code A | —63,500 at $0.00 | filing |
| 23 Feb 2021filed 25 Feb 2021 | XGN ExagenDiagnostics & Labs | SEC FORM 4 Code A | —37,500 at $0.00 | filing |
| 23 Feb 2021filed 25 Feb 2021 | XGN Exagenoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —12,500 at $0.00 | filing |
| 9 Jan 2020filed 9 Jan 2020 | XGN Exagenoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —52,500 at $0.00 | filing |
| 18 Sep 2019filed 20 Sep 2019 | XGN Exagenoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —21,635 at $0.00 | filing |
News
Canaccord Genuity Group Issues Positive Forecast for Exagen (NASDAQ:XGN) Stock PriceXGN · themarketsdaily.com · 19 Oct 2026Centene (NYSE:CNC) vs. Exagen (NASDAQ:XGN) Head to Head SurveyXGN · themarketsdaily.com · 14 Oct 2026
0 headlines in the last 90 days name Kamal Adawi; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.